• DUSS · OTC
  • EMXC · OTC
  • TYTN · OTC
  • TDGI · OTC
  • Mid-Day Penny Stock Report CBAI,FMCC,ACAD,KATX

    Written by: Dana Salvo

    Bookmark and Share

    Boca Raton,FL July 29, 2010 -THE STOCK WIZARDS FOCUS LISTS INCLUDES: (OTCBB: CBAI ) Cord Blood America, Inc. (OTCBB: FMCC) Freddie Mac (NASDAQ:ACAD)  ACADIA Pharmaceuticals, Inc. (OTC: KATX) KAT Exploration Inc.

    Learn to Trade Small Cap Penny Stocks from Expert Traders. Visit The TSW Website at http://www.TheStockWizards.net learn to make big profits.

    Receive Our Hot OTC Newsletter Put out Every Weekend Highlighting Penny Stocks, Small Cap & Micro Cap Stocks before They Breakout. The Hottest weekend Newsletter Around.


    (OTCBB: CBAI — Cord Blood America, Inc.)


    Cord Blood America Details Six Months of Success

    LAS VEGAS, July 29, 2010 — Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced highlights for the six-month period ended June 30, 2010. The Company believes the period was the most significant and eventful in its history.

    “If we can continue this pace of expansion and acquisition, we will fast approach our goal of becoming the most significant stem cell company in the world,” Matthew Schissler, co-founder and CEO, said.

    The year started with more than 200 investors gathered in Las Vegas, along with a number of local and state dignitaries, for the Grand Opening of the Company’s 17,000 square foot stem cell laboratory and headquarters, which is believed to be the largest cryogenic storage facility and stem cell laboratory in the U.S.

    Also in January the Company announced it had received commitments for up to $16.8 million to fund its business strategies in 2010, including acquisitions, and that it had signed a letter of intent to process and store cord blood specimens for BioCells, Inc., headquartered in Argentina, one of South America’s largest stem cell companies with revenues topping $1.5 million (U.S.) annually. That agreement was finalized in February and in April Cord Blood America announced its intention to purchase a controlling interest in the profitable Buenos Aires firm. Also in February the Company named Shamoon Ahmad, M.D., President of the Nevada Oncology Society with a distinguished record in medical oncology, as Director of its Medical Advisory Board.

    March 2010 began with the Company announcing it had acquired controlling interest in stellacure GmbH, one of the largest cord blood banking services in Germany, operating in conjunction with the German Red Cross. “This gives us the foundation needed to expand our services throughout Europe,” Mr. Schissler said. Revenues from stellacure are projected to top $1 million in 2010. The month of March ended with Cord Blood America announcing it has signed a License and Cooperation Agreement for the processing and storage of umbilical cord blood in China. “Our plan is to create the world’s largest cord blood bank in the world’s most populous nation,” Mr. Schissler said.

    Also in April 2010 Cord Blood America announced it had signed an agreement to provide placenta collection services for therapeutic transplantation for a large, well-respected U.S. tissue bank. “These stem cells are used in treatments against disorders such as sickle cell disease and leukemia and research is ongoing on utilizing these cells in treatments for diabetes, heart disease, stroke and other major medical conditions,” Mr. Schissler said.

    Finally, to round out the six months of activity, Cord Blood America announced in May 2010 its “Afford-A-Cord” program, which significantly reduces the initial cost of storing umbilical cord blood stem cells, allowing more families to participate in taking advantage of the real and potential medical advances from the use of stem cells. In June 2010, in an analyst interview, Mr. Schissler said the unique new program could significantly increase new account additions.

    “CBAI set its top-line focused goals for investors at the beginning of the year: Organic Growth, Acquisition, and Diversification of Revenue Streams. We believe in the first half of 2010 that we have built a strong foundation to support those objectives and we’re excited about the second half of 2010. We look forward to continued pursuit of these important goals, as well as announcing additional news that we believe will reward and benefit all of CBAI’s loyal shareholders,” Mr. Schissler said.

    About Cord Blood America

    Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

    Technical Outlook:

    CBAI Traders and Investors are watching the 50 day moving average very closely. A Breakout above .006 will spark some momentum buying in the stock. . CBAI is currently up 3.37% on heavy volume of 5.2 million shares in the morning session.


    (OTCBB: FMCC— Freddie Mac)

    Current News !!

    Freddie Mac Will Not Issue a Reference Notes(R) Security on July 29, 2010

    MCLEAN, Va., July 29, 2010 — Freddie Mac (OTC Bulletin Board: FMCC) announced today that it will not issue a Reference Notes(R) security on July 29, 2010. The company’s 2010 Reference Notes calendar designates dates that it may use to announce the issuance of Reference Notes securities.

    This announcement is not an offer to sell any Freddie Mac securities. Offers for any given security are made only through applicable offering circulars and related supplements, which incorporate Freddie Mac’s Annual Report on Form 10-K for the year ended December 31, 2009, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2010, and all documents that Freddie Mac files with the SEC pursuant to Section 13(a), 13(c) or 14 of the Securities Exchange Act of 1934, excluding any information “furnished” to the SEC on Form 8-K.

    Freddie Mac’s press releases sometimes contain forward-looking statements. A description of factors that could cause actual results to differ materially from the expectations expressed in these and other forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2009 and its reports on Form 10-Q and Form 8-K, filed with the SEC and available on the Investor Relations page of the company’s Web site at www.FreddieMac.com/investors and the SEC’s Web site at www.sec.gov.

    Freddie Mac was established by Congress in 1970 to provide liquidity, stability and affordability to the nation’s residential mortgage markets. Freddie Mac supports communities across the nation by providing mortgage capital to lenders. Over the years, Freddie Mac has made home possible for one in six homebuyers and more than five million renters. www.FreddieMac.com


    (NASDAQ: ACAD — ACADIA Pharmaceuticals, Inc.)

    Current News !!

    ACADIA Pharmaceuticals Announces Initiation of New Phase III Trial with Pimavanserin for Parkinson’s Disease Psychosis

    SAN DIEGO, Jul 29, 2010 — ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson’s disease psychosis (PDP).

    “This Phase III trial builds on the signals of efficacy observed in our earlier PDP studies and uses a refined study design that we expect will help mitigate the placebo response, reduce variability and enhance sensitivity in measuring the efficacy of pimavanserin in PDP patients,” said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA Pharmaceuticals. “We believe pimavanserin has an ideal profile to effectively treat PDP without impairing motor function and, therefore, provides the potential for an important advance in therapy for patients suffering from this large unmet medical need.”

    Trial Design

    The new Phase III trial (the -020 Study) is a multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy, tolerability and safety of pimavanserin in patients with PDP. The -020 Study is expected to enroll about 200 patients at clinical sites located in North America. Patients in the trial will be randomized on a one-to-one basis to two study arms and will receive oral doses of either 40 mg of pimavanserin or placebo once-daily for six weeks. Patients also will continue to receive stable doses of their existing dopamine replacement therapy used to manage the motoric symptoms of Parkinson’s disease. The primary endpoint of the -020 Study is antipsychotic efficacy as measured using a group of nine items from the hallucinations and delusions domains of the Scale for the Assessment of Positive Symptoms (SAPS). The primary endpoint will be assessed using centralized ratings. Motoric tolerability will be a key secondary endpoint in the trial and will be measured using Parts II and III of the Unified Parkinson’s Disease Rating Scale (UPDRS).

    In addition to the -020 Study, ACADIA is continuing to conduct an open-label safety extension study (the -015 Study) that enrolled patients who completed either of two earlier Phase III PDP trials. Patients who complete the -020 Study also will have the opportunity to enroll in the -015 Study if, in the opinion of the treating physician, the patient may benefit from continued treatment with pimavanserin.

    About Pimavanserin

    Pimavanserin is a 5-HT2A receptor inverse agonist in Phase III development as a treatment for Parkinson’s disease psychosis. This new chemical entity, which was discovered by ACADIA, is a small molecule that can be taken orally as a tablet once-a-day. ACADIA and Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corporation, have formed a collaboration to develop and commercialize pimavanserin for neurological and psychiatric indications, including Parkinson’s disease psychosis, schizophrenia, and Alzheimer’s disease psychosis, in the United States and Canada. ACADIA retains rights to pimavanserin in the rest of the world.

    About Parkinson’s Disease Psychosis

    According to the National Parkinson Foundation, over 1.5 million people in the United States suffer from Parkinson’s disease. Up to 40 percent of patients with Parkinson’s disease may develop psychotic symptoms, commonly consisting of visual hallucinations and delusions. Currently, there is no therapy in the United States approved to treat PDP. The development of psychosis in patients with Parkinson’s disease often disrupts their ability to perform many of the activities of daily living and is associated with increased caregiver burden, nursing home placement, and increased mortality.

    About ACADIA Pharmaceuticals

    ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA is developing a portfolio consisting of four product candidates including pimavanserin, which is being developed for three separate neurological and psychiatric indications in collaboration with Biovail. These indications are Parkinson’s disease psychosis, which is in Phase III development, co-therapy for schizophrenia, which is in Phase III planning, and Alzheimer’s disease psychosis, for which ACADIA is planning to initiate a Phase II feasibility study. In addition to pimavanserin, ACADIA has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. All of the product candidates in ACADIA’s product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive e-mail alerts.


    (OTC: KATX — KAT Exploration Inc.)


    KAT Exploration and Bella Viaggio, Inc. Welcome “Senior Vice President of Capital Projects” to Board of Directors

    MOUNT PEARL, NEWFOUNDLAND, Jul 29, 2010 — KAT Exploration Inc. (PINKSHEETS: KATX) (www.KATexploration.com) and Bella Viaggio, Inc. (OTCBB: BVIG) are very pleased to announce that J. Wayne Pickett has agreed to join the companies as a director and “Senior Vice President of Capital Projects.” Mr. Ken Stead, CEO, commented that “on behalf of the board of directors, we are delighted to have someone with this caliber of a geological background to oversee all the company’s projects as we move forward ever so rapidly.” All present and future geologists along with field crews will work under the direction of Mr. Pickett.

    Please check the link for Mr. Pickett’s resume.


    Also, on June 26th, 2010, 77 new claims were staked around the most Northern claims of the Handcamp property as more new discoveries have been found. This latest discovery is approximately 2 kms to the North of the main Handcamp showing and appears to be an extension of the latest north western anomalies recently discovered through Induced Polarization (IP). This mineralized zone contains very impressive massive sulfides and samples have been sent to the lab for gold and base metal analysis. No drilling or trenching has taken place in those new areas thus far but will be part of another drill phase as we continue to move the project forward.

    See attached pictures.

    Nine drill holes have been completed to date with all holes intersecting mineralization. Hole #7 tested the mineralized structure at 180 meters (612ft) down section and intersected mineralization over a width of 30 meters. This is extremely encouraging as we now know that, not only does the strike length of the mineralized structure continue for at least a minimum of 1400 meters and open at both ends, it has a minimum depth of 180 meters and also open at depth. With new mineralized structures being discovered to the west and far north, this increases the potential of the property significantly.

    Results are beginning to be received from the lab and Jim Weick along with Wayne Pickett will begin the compilation of these results which will be published in an upcoming press release.


    About TheStockWizards.net

    Please visit our website for Disclosures and Disclaimers and any conflicts of interest that there may be. http://thestockwizards.net/about/disclaimer/

    Forward-Looking Statement: This press release includes “forward-looking statements” within the meaning of the federal securities laws, commonly identified by such terms as “believes,” “looking ahead,” “anticipates,” “estimates” and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company’s projections and expectations are disclosed in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

    TheStockWizards.net is not a registered investment advisers or broker/dealer.

    TheStockWizards.net makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high risk.

    Contact Info:  E-mail: [email protected] thestockwizards.net

    TheStockWizards.net 954-592-4770

    July 29, 2010 @ 5:33 pm Trackback URL Posted in Hot Stocks and tagged with , , , , , , , , , , , , , , , , , .